Gamma-glutamyl transpeptidase: redox regulation and drug resistance

• Published in: Advances in cancer research Vol. 122; pp. 103 - 141
• Main Author: Hanigan, Marie H
• Format: Journal Article
• Language: English
• Published: United States 2014
• Subjects: Animals; Catalysis; Cystine - chemistry; Drug Resistance, Neoplasm; gamma-Glutamyltransferase - blood; gamma-Glutamyltransferase - physiology; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glutathione - chemistry; Humans; Mice; Neoplasms - metabolism; Neoplasms - pathology; Neoplasms - therapy; Oxidants - chemistry; Oxidation-Reduction; Oxygen - chemistry; Rats; Cysteine; Gamma-glutamyl transferase; Gamma-glutamyl transpeptidase; Glutathione
• ISSN: 2162-5557; 0065-230X; 2162-5557
• DOI: 10.1016/B978-0-12-420117-0.00003-7

The expression of gamma-glutamyl transpeptidase (GGT) is essential to maintaining cysteine levels in the body. GGT is a cell surface enzyme that hydrolyzes the gamma-glutamyl bond of extracellular reduced and oxidized glutathione, initiating their cleavage into glutamate, cysteine (cystine), and glycine. GGT is normally expressed on the apical surface of ducts and glands, salvaging the amino acids from glutathione in the ductal fluids. GGT in tumors is expressed over the entire cell membrane and provides tumors with access to additional cysteine and cystine from reduced and oxidized glutathione in the blood and interstitial fluid. Cysteine is rate-limiting for glutathione synthesis in cells under oxidative stress. The induction of GGT is observed in tumors with elevated levels of intracellular glutathione. Studies in models of hepatocarcinogenesis show that GGT expression in foci of preneoplastic hepatocytes provides a selective advantage to the cells during tumor promotion with agents that deplete intracellular glutathione. Similarly, expression of GGT in tumors enables cells to maintain elevated levels of intracellular glutathione and to rapidly replenish glutathione during treatment with prooxidant anticancer therapy. In the clinic, the expression of GGT in tumors is correlated with drug resistance. The inhibitors of GGT block GGT-positive tumors from accessing the cysteine in extracellular glutathione. They also inhibit GGT activity in the kidney, which results in the excretion of GSH in the urine and a rapid decrease in blood cysteine levels, leading to depletion of intracellular GSH in both GGT-positive and GGT-negative tumors. GGT inhibitors are being developed for clinical use to sensitize tumors to chemotherapy.